Replies to post #17983 on GTC Biotherapeutics (fka GTCB)

[Black_Knight_765]

>Very so. Atryn of course not being "currently on the market".<

The wording in Lundbeck's press release was '... the products Ovation markets include Atryn, just approved...'

Is 'the products Ovation markets' different from 'currently on the market? That seems like pretty fine hair splitting to me.

This was obviously in the works for a while and a decision was made to wait to announce until after the FDA decision. Could be a coincidence, but perhaps FDA approval of Atryn was viewed as enhancing the perception of the value of Ovation.

Reading the entire Lundbeck press release does not sound anti-Atryn at all.

From Lundbeck's press release:

Strategic rationale

The acquisition of Ovation delivers on Lundbeck's strategic goal to build a commercial infrastructure in the US. Ovation is a private, US-based, profitable and fast growing company, with a broad portfolio of marketed products and an attractive pipeline of new, innovative products primarily focused on CNS.

.....

Products on the market to address CNS disorders include Xenazine® for chorea associated with Huntington's disease, Tranxene® for anxiety disorders, Nembutal® for acute convulsive disorders, Cogentin® for Parkinson's disease and Desoxyn® for ADHD. Outside CNS disorders the products Ovation markets include ATryn®, just approved by the U.S. Food and Drug Administration for the prevention of thromboembolic events in hereditary antithrombin deficient (HAD) patients in high-risk situations such as surgery or childbirth procedures, a portfolio of hospital-based products, and haematology/oncology therapies, including Panthematin® for recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women.

http://www.lundbeck.com/investor/releases/ReleaseDetails/Release_1288536_EN.asp